Schond Greenway
Director of Finance/CFO chez MIND MEDICINE (MINDMED) INC.
Fortune : 2 M $ au 31/03/2024
Profil
Schond L.
Greenway is currently the Chief Financial Officer at Mind Medicine (MindMed), Inc. He previously worked as the Executive Director-Strategy & IR at Halozyme Therapeutics, Inc. from 2013 to 2016.
He also held the position of VP-Investor Relations & Strategic Planning at DURECT Corp.
and Vice President-Healthcare at Barclays Capital, Inc. Mr. Greenway was the VP & Global Head-Investor Relations at Mesoblast Ltd.
from 2016 to 2021.
He then worked as the Chief Financial Officer & Treasurer at Avalo Therapeutics, Inc. from 2021 to 2022.
Mr. Greenway received his undergraduate degree from Florida A&M University and his MBA from the University of Virginia Darden School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 25/03/2024 | 211 057 ( 0,30% ) | 2 M $ | 31/03/2024 |
Postes actifs de Schond Greenway
| Sociétés | Poste | Début |
|---|---|---|
| MIND MEDICINE (MINDMED) INC. | Director of Finance/CFO | 23/05/2022 |
Anciens postes connus de Schond Greenway
| Sociétés | Poste | Fin |
|---|---|---|
| AVALO THERAPEUTICS, INC. | Director of Finance/CFO | 14/02/2022 |
| MESOBLAST LIMITED | Investor Relations Contact | 01/02/2021 |
| HALOZYME THERAPEUTICS, INC. | Investor Relations Contact | 01/01/2016 |
| DURECT CORPORATION | Public Communications Contact | - |
Barclays Capital, Inc.
 Barclays Capital, Inc. Investment Banks/BrokersFinance Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team. | Corporate Officer/Principal | - |
Formation de Schond Greenway
| Florida A&M University | Undergraduate Degree |
| University of Virginia Darden School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| DURECT CORPORATION | Health Technology |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| MESOBLAST LIMITED | Health Technology |
| AVALO THERAPEUTICS, INC. | Health Technology |
| MIND MEDICINE (MINDMED) INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Barclays Capital, Inc.
Barclays Capital, Inc. Investment Banks/BrokersFinance Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team. | Finance |
